SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

, , , , , , , , , , , , ,

FEBS Letters, 350(2-3), 240-244 (1994) .


SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes. After intraperitoneal or oral administration SR141716A antagonises classical pharmacological and behavioural effects of cannabinoid receptor agonists. This compound should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.

Add your rating and review

If all scientific publications that you have read were ranked according to their scientific quality and importance from 0% (worst) to 100% (best), where would you place this publication? Please rate by selecting a range.

0% - 100%

This publication ranks between % and % of publications that I have read in terms of scientific quality and importance.

Keep my rating and review anonymous
Show publicly that I gave the rating and I wrote the review